Policy & Regulation
Varian Named to AmMax Bio Board
4 March 2021 - - US-based biopharmaceutical company AmMax Bio, Inc has appointed John Varian as an independent board member, the company said.

Varian brings a wealth of industry experience to the board of AmMax, having held leadership positions in business development, alliance management, capital fund-raising, and new product launches.

Varian has served as the CEO and director of XOMA, an antibody business, where he led the financial restructuring of the company. Prior to joining XOMA, he served as the COO of Aryx Pharmaceuticals and helped lead the company through its initial public offering.

He has also served as CFO of Anergen, Genset SA and Neurex Corp, and as senior vice president of Finance with Elan Corp.

Varian currently serves on the board of directors for Sellas Life Sciences (NASDAQ: SLS) and is chairman of the audit committee. He has previously served on the boards of XOMA Corp. (NASDAQ: XOMA), Versartis Corp. (NASDAQ: VSAR), and Egalet Corp.

He received his B.B.A. from Western Michigan University and is a Certified Public Accountant.

AmMax was founded in March 2020 to develop therapies under an exclusive worldwide license from Amgen, Inc. that leverage the diverse and critical roles played by the CSF1 signaling pathway for macrophage regulation throughout the body.

Based on a potent monoclonal antibody named AMB-05X, the company is using this proprietary platform to build a portfolio of first-in-class and best-in-class therapies that address diseases with significant unmet medical needs and substantial commercial potential.

AmMax's drug development pipeline includes Phase 2 clinical programs for tenosynovial giant cell tumor and idiopathic pulmonary fibrosis, in addition to earlier stage programs for polycystic kidney diseases and certain ocular disorders.


Related Headlines